Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat

References

• Seferović PM, Vardas P, Jankowska EA, et al. The Heart Failure Association atlas: heart failure epidemiology and management statistics 2019. Eur J Heart Fail. 2021;23(6):906–914. doi:10.1002/ejhf.2143
   PubMed Web of Science ®Google Scholar
• Rodríguez-Padial L, Bertomeu V, Elola FJ, et al. Quality improvement strategy of the Spanish Society of Cardiology: the RECALCAR registry. J Am Coll Cardiol. 2016;68(10):1140–1142. doi:10.1016/j.jacc.2016.07.723
   PubMedGoogle Scholar
• RECALCAR Registry 2020. Healthcare for patients with heart disease in the national health system. Available from: https://secardiologia.es/images/institucional/sec-calidad/sec-recalcar/RECALCAR_2020_FINAL.pdf. Accessed March 13, 2023.
   Google Scholar
• Delgado JF, Ferrero Gregori A, Fernández LM, et al. Patient-associated predictors of 15- and 30-day readmission after hospitalization for acute heart failure. Curr Heart Fail Rep. 2019;16(6):304–314. doi:10.1007/s11897-019-00442-1
   PubMedGoogle Scholar
• Butler J, Yang M, Manzi MA, et al. Clinical course of patients with worsening heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019;73(8):935–944. doi:10.1016/j.jacc.2018.11.049
   PubMed Web of Science ®Google Scholar
• Farré N, Vela E, Clèries M, et al. Medical resource use and expenditure in patients with chronic heart failure: a population-based analysis of 88 195 patients. Eur J Heart Fail. 2016;18(9):1132–1140. doi:10.1002/ejhf.549
   PubMed Web of Science ®Google Scholar
• Escobar C, Varela L, Palacios B, et al. Costs and healthcare utilisation of patients with heart failure in Spain. BMC Health Serv Res. 2020;20(1):964. doi:10.1186/s12913-020-05828-9
   PubMed Web of Science ®Google Scholar
• Greene SJ, Mentz RJ, Felker GM. Outpatient worsening heart failure as a target for therapy: a review. JAMA Cardiol. 2018;3(3):252–259. doi:10.1001/jamacardio.2017.5250
   PubMed Web of Science ®Google Scholar
• Greene SJ, Fonarow GC, Butler J. Risk profiles in heart failure: baseline, residual, worsening, and advanced heart failure risk. Circ Heart Fail. 2020;13(6):e007132. doi:10.1161/CIRCHEARTFAILURE.120.007132
   PubMedGoogle Scholar
• Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J. 2007;154(2):260–266. doi:10.1016/j.ahj.2007.01.041
   PubMed Web of Science ®Google Scholar
• Rechenberg K, Cousin L, Redwine L. Mindfulness, anxiety symptoms, and quality of life in heart failure. J Cardiovasc Nurs. 2020;35(4):358–363. doi:10.1097/JCN.0000000000000630
   PubMedGoogle Scholar
• Tavazzi L, Senni M, Metra M, et al. Multicenter prospective observational study on acute and chronic heart failure: one-year follow-up results of IN-HF (Italian network on heart failure) outcome registry. Circ Heart Fail. 2013;6(3):473–481. doi:10.1161/CIRCHEARTFAILURE.112.000161
   PubMed Web of Science ®Google Scholar
• Solomon SD, Claggett B, Packer M, et al. Efficacy of sacubitril/valsartan relative to a prior decompensation: the PARADIGM-HF trial. JACC Heart Fail. 2016;4(10):816–822. doi:10.1016/j.jchf.2016.05.002
   PubMed Web of Science ®Google Scholar
• McDonagh T, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi:10.1093/eurheartj/ehab368
   PubMed Web of Science ®Google Scholar
• Takeda A, Martin N, Taylor RS, Taylor SJ. Disease management interventions for heart failure. Cochrane Database Syst Rev. 2019;1(1):CD002752. doi:10.1002/14651858.CD002752.pub4
   PubMedGoogle Scholar
• Takeda A, Taylor SJ, Taylor RS, Khan F, Krum H, Underwood M. Clinical service organisation for heart failure. Cochrane Database Syst Rev. 2012;9:CD002752. doi:10.1002/14651858.CD002752.pub3
   PubMed Web of Science ®Google Scholar
• Girerd N, Von Hunolstein JJ, Pellicori P, et al. Therapeutic inertia in the pharmacological management of heart failure with reduced ejection fraction. ESC Heart Fail. 2022;9(4):2063–2069. doi:10.1002/ehf2.13929
   PubMed Web of Science ®Google Scholar
• Comín-Colet J, Enjuanes C, Lupón J, Cainzos-Achirica M, Badosa N, Verdú JM. Transitions of care between acute and chronic heart failure: critical steps in the design of a multidisciplinary care model for the prevention of rehospitalization. Rev Esp Cardiol. 2016;69(10):951–961. doi:10.1016/j.rec.2016.05.001
   PubMedGoogle Scholar
• Comín-Colet J, Verdú-Rotellar JM, Vela E, et al. Efficacy of an integrated hospital-primary care program for heart failure: a population-based analysis of 56,742 patients. Rev Esp Cardiol. 2014;67(4):283–293. doi:10.1016/j.rec.2013.12.005
   PubMed Web of Science ®Google Scholar
• McCambridge J, Keane C, Walshe M, et al. The prehospital patient pathway and experience of care with acute heart failure: a comparison of two health care systems. ESC Heart Fail. 2021;8(2):1076–1084. doi:10.1002/ehf2.13089
   PubMedGoogle Scholar
• Medical Advisory Secretariat. Community-based care for the specialized management of heart failure: an evidence-based analysis. Ont Health Technol Assess Ser. 2009;9(17):1–42.
   Google Scholar
• SEC-PRIMARIA. Heart failure process. Available from: https://secardiologia.es/images/institucional/sec-calidad/sec-primaria/SEC-AP_IC_2021_20210922_DEFINITIVO.pdf. Accessed March 13, 2023.
   Google Scholar
• Barrios V, Cosín-Sales J, Bravo M, et al. Telemedicine consultation for the clinical cardiologists in the era of COVID-19: present and future. Consensus document of the Spanish society of cardiology. Rev Esp Cardiol. 2020;73(11):910–918. doi:10.1016/j.rec.2020.06.032
   PubMed Web of Science ®Google Scholar
• Alvarez P, Sianis A, Brown J, Ali A, Briasoulis A. Chronic disease management in heart failure: focus on telemedicine and remote monitoring. Rev Cardiovasc Med. 2021;22(2):403–413. doi:10.31083/j.rcm2202046
   PubMedGoogle Scholar
• Imberti JF, Tosetti A, Mei DA, Maisano A, Boriani G. Remote monitoring and telemedicine in heart failure: implementation and benefits. Curr Cardiol Rep. 2021;23(6):55. doi:10.1007/s11886-021-01487-2
   PubMed Web of Science ®Google Scholar
• Silva-Cardoso J, Juanatey JRG, Comin-Colet J, Sousa JM, Cavalheiro A, Moreira E. The future of telemedicine in the management of heart failure patients. Card Fail Rev. 2021;7:e11. doi:10.15420/cfr.2020.32
   PubMedGoogle Scholar
• Yun S, Enjuanes C, Calero E, et al. Study design of Heart failure Events reduction with Remote Monitoring and eHealth Support (HERMeS). ESC Heart Fail. 2020;7(6):4448–4457. doi:10.1002/ehf2.12962
   PubMedGoogle Scholar
• Yun S, Enjuanes C, Calero-Molina E, et al. Usefulness of telemedicine-based heart failure monitoring according to ‘eHealth literacy’ domains: insights from the iCOR randomized controlled trial. Eur J Intern Med. 2022;101:56–67. doi:10.1016/j.ejim.2022.04.008
   PubMedGoogle Scholar
• Yun S, Enjuanes C, Calero-Molina E, et al. Effectiveness of telemedicine in patients with heart failure according to frailty phenotypes: insights from the iCOR randomised controlled trial. Eur J Intern Med. 2022;96:49–59. doi:10.1016/j.ejim.2021.09.021
   PubMed Web of Science ®Google Scholar
• Comín-Colet J, Enjuanes C, Verdú-Rotellar JM, et al. Impact on clinical events and healthcare costs of adding telemedicine to multidisciplinary disease management programmes for heart failure: results of a randomized controlled trial. J Telemed Telecare. 2016;22(5):282–295. doi:10.1177/1357633X15600583
   PubMedGoogle Scholar
• Jiménez-Marrero S, Yun S, Cainzos-Achirica M, et al. Impact of telemedicine on the clinical outcomes and healthcare costs of patients with chronic heart failure and mid-range or preserved ejection fraction managed in a multidisciplinary chronic heart failure programme: a sub-analysis of the iCOR randomized trial. J Telemed Telecare. 2020;26(1–2):64–72. doi:10.1177/1357633X18796439
   PubMedGoogle Scholar
• Brownell NK, Ziaeian B, Fonarow GC. The gap to fill: rationale for rapid initiation and optimal titration of comprehensive disease-modifying medical therapy for heart failure with reduced ejection fraction. Card Fail Rev. 2021;7:e18. doi:10.15420/cfr.2021.18
   PubMedGoogle Scholar
• Sayer G, Bhat G. The renin-angiotensin-aldosterone system and heart failure. Cardiol Clin. 2014;32(1):21–32. doi:10.1016/j.ccl.2013.09.002
   PubMed Web of Science ®Google Scholar
• Antoine S, Vaidya G, Imam H, Villarreal D. Pathophysiologic mechanisms in heart failure: role of the sympathetic nervous system. Am J Med Sci. 2017;353(1):27–30. doi:10.1016/j.amjms.2016.06.016
   PubMed Web of Science ®Google Scholar
• Hubers SA, Brown NJ. Combined angiotensin receptor antagonism and neprilysin inhibition. Circulation. 2016;133(11):1115–1124. doi:10.1161/CIRCULATIONAHA.115.018622
   PubMed Web of Science ®Google Scholar
• Nightingale B. A review of the proposed mechanistic actions of sodium glucose cotransporter-2 inhibitors in the treatment of heart failure. Cardiol Res. 2021;12(2):60–66. doi:10.14740/cr1221
   PubMed Web of Science ®Google Scholar
• Sandner P, Zimmer DP, Milne GT, Follmann M, Hobbs A, Stasch JP. Soluble guanylate cyclase stimulators and activators. Handb Exp Pharmacol. 2021;264:355–394. doi:10.1007/164_2018_197
   PubMedGoogle Scholar
• Sandner P, Follmann M, Becker-Pelster E, et al. Soluble GC stimulators and activators: past, present and future. Br J Pharmacol. 2021. doi:10.1111/bph.15698
   Web of Science ®Google Scholar
• McMurray JJV, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction? A redefinition of evidence-based medicine. Circulation. 2021;143(9):875–877. doi:10.1161/CIRCULATIONAHA.120.052926
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883–1893. doi:10.1056/NEJMoa1915928
   PubMed Web of Science ®Google Scholar
• Lam CSP, Mulder H, Lopatin Y, et al. Blood pressure and safety events with vericiguat in the Victoria trial. J Am Heart Assoc. 2021;10(22):e021094. doi:10.1161/JAHA.121.021094
   PubMed Web of Science ®Google Scholar
• Voors AA, Mulder H, Reyes E, et al. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the Victoria (Vericiguat global study in subjects with HFrEF) trial. Eur J Heart Fail. 2021;23(8):1313–1321. doi:10.1002/ejhf.2221
   PubMed Web of Science ®Google Scholar
• Lam CSP, Giczewska A, Sliwa K, et al. Clinical outcomes and response to vericiguat according to index heart failure event: insights from the Victoria trial. JAMA Cardiol. 2021;6(6):706–712. doi:10.1001/jamacardio.2020.6455
   PubMed Web of Science ®Google Scholar
• Ezekowitz JA, O’Connor CM, Troughton RW, et al. N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail. 2020;8(11):931–939. doi:10.1016/j.jchf.2020.08.008
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004. doi:10.1056/NEJMoa1409077
   PubMed Web of Science ®Google Scholar
• McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi:10.1056/NEJMoa1911303
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi:10.1056/NEJMoa2022190
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022;79(17):e263–e421. doi:10.1016/j.jacc.2021.12.012
   PubMed Web of Science ®Google Scholar
• McDonald M, Virani S, Chan M, et al. CCS/CHFS heart failure guidelines update: defining a new pharmacologic standard of care for heart failure with reduced ejection fraction. Can J Cardiol. 2021;37(4):531–546. doi:10.1016/j.cjca.2021.01.017
   PubMed Web of Science ®Google Scholar
• González-Juanatey JR, Anguita-Sánchez M, Bayes-Genís A, et al. Vericiguat in heart failure: from scientific evidence to clinical practice. Rev Clin Esp. 2022;222(6):359–369. doi:10.1016/j.rceng.2021.12.006
   PubMed Web of Science ®Google Scholar
• Tromp J, Ouwerkerk W, van Veldhuisen DJ, et al. A systematic review and network meta-analysis of pharmacological treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2022;10(2):73–84. doi:10.1016/j.jchf.2021.09.004
   PubMed Web of Science ®Google Scholar
• Greene SJ, Tan X, Yeh YC, et al. Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. Heart Fail Rev. 2022;27(3):741–753. doi:10.1007/s10741-021-10077-x
   PubMedGoogle Scholar
• Vericiguat. Summary of product characteristics; 2021. Available from: https://www.ema.europa.eu/en/documents/assessment-report/verquvo-epar-public-assessment-report_en.pdf. Accessed March 13, 2023.
   Google Scholar